Bayer Archives -

Bayer chief executive Werner Baumann has been under fire from investors since he spearheaded the acquisition of agrochemical

Report claims Bayer is already hunting for a new CEO

https://pharmaphorum.com/news/report-claims-bayer-is-already-hunting-for-a-new-ceo/

News/ News/ News/ R&D/ Sales and Marketing

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseases

Phil Taylor age-related macular degeneration, Bayer, diabetic macular oedema, Eylea, ophthalmology, Regeneron, Roche, Vabysmo 0 Comment

A higher dose of Regeneron and Bayer’s Eylea given every three or four months has shown efficacy in

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseases

https://pharmaphorum.com/news/eylea-data-gives-regeneron-bayer-a-lift-in-ophthalmic-diseases/

Patients/ Views & Analysis/ Views and analysis

Bayer sets out a proposed basis for science-based self-care products

Amanda Barrell Bayer, healthcare, scientific principles, self-care 0 Comment

The healthcare sector has a “moral imperative” to help people navigate the self-care industry, says pharma giant. Recent

Bayer sets out a proposed basis for science-based self-care products

https://pharmaphorum.com/patients/bayer-sets-out-a-proposed-basis-for-science-based-self-care-products/

News/ News/ R&D

ESC22: Despite trial misses, Bayer preps phase 3 for asundexian

Phil Taylor asundexian, Bayer, Bristol-Myers Squibb, cardiovascular disease, Johnson & Johnson, milvexian 0 Comment

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new

ESC22: Despite trial misses, Bayer preps phase 3 for asundexian

https://pharmaphorum.com/news/esc22-despite-trial-misses-bayer-preps-phase-3-for-asundexian/

News/ News/ R&D

Merck chases Bayer/Ionis with fast track for Factor XI drug

Phil Taylor anticoagulant, Bayer, dialysis, Ionis Pharmaceuticals, Merck & Co, nephrology, renal disease 0 Comment

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for

Merck chases Bayer/Ionis with fast track for Factor XI drug

https://pharmaphorum.com/news/merck-chases-bayer-ionis-with-fast-track-for-factor-xi-drug/

News/ News/ R&D

Bayer unit BrainVectis cleared to start Huntington gene therapy trial

Phil Taylor AskBio, Bayer, BrainVectis, gene therapy, Huntington's disease 0 Comment

France’s BrainVectis, a subsidiary of Bayer’s Asklepios BioPharma (AskBio) unit, has been given the green light by regulators

Bayer unit BrainVectis cleared to start Huntington gene therapy trial

https://pharmaphorum.com/news/bayer-unit-brainvectis-cleared-to-start-huntington-gene-therapy-trial/

Mature Woman Experiencing Hot Flush From Menopause

Market Access/ News/ News

Astellas files menopause drug fezolinetant in US, setting up Feb verdict

Phil Taylor Astellas, Bayer, elinzanetant, fezolinetant, menopause, regulatory, women's health 0 Comment

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of

Astellas files menopause drug fezolinetant in US, setting up Feb verdict

https://pharmaphorum.com/news/astellas-files-menopause-drug-fezolinetant-in-us-setting-up-feb-verdict/

News/ News/ News/ Oncology/ Sales and Marketing

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Phil Taylor Bayer, Erleada, Nubeqa, Oncology, Orion, Prostate cancer, regulatory approval, Xtandi 0 Comment

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

https://pharmaphorum.com/news/bayer-bags-swift-ok-for-nubeqa-in-metastatic-prostate-cancer/

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

Trending

Bayer

Login